ISDA

Deposition Date 2013-11-04

Release Date 2014-01-22

Last Version Date 2024-02-28

Entry Detail

PDB ID:

4NH9

Keywords:

CHAPERONE

Title:

Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.77 Å

R-Value Free:

0.27

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Endoplasmin
Gene (Uniprot):HSP90B1
Chain IDs:A
Chain Length:273
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P14625 Pfam ID:PF13589

Ligand Molecules

2LC

Primary Citation

Correlation between chemotype-dependent binding conformations of HSP90 alpha / beta and isoform selectivity-Implications for the structure-based design of HSP90 alpha / beta selective inhibitors for treating neurodegenerative diseases.

Ernst, J.T, Liu, M, Zuccola, H, Neubert, T, Beaumont, K, Turnbull, A, Kallel, A, Vought, B, Stamos, D.Show

Bioorg.Med.Chem.Lett. 24 204 208 (2014)

PMID: 24332488 DOI: 10.1016/j.bmcl.2013.11.036

Abstact

HSP90 continues to be a target of interest for neurodegeneration indications. Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro. Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity. The rational design of HSP90α/β inhibitors selective versus the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities. Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.

Legend

Protein

Chemical

Disease

Primary Citation of related structures